Phase I trial of lestaurtinib for children with refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 1057-1065

  Minturn, Jane E ^a   Evans, Audrey E ^a   Villablanca, Judith G ^b   Yanik, Gregory A ^c   Park, Julie R ^d   Shusterman, Suzanne ^e   Groshen, Susan ^b   Hellriegel, Edward T ^f   Bensen Kennedy, Debra ^f   Matthay, Katherine K ^g   Brodeur, Garrett M ^a   Maris, John M ^a,h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CEPHALON INC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Lestaurtinib; Neuroblastoma; Receptor tyrosine kinase; Signal transduction; Targeted therapy

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; LESTAURTINIB;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASYMPTOMATIC DISEASE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUTROPENIA; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CARBAZOLES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; NEUROBLASTOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, TRKB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054754771     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1581-4     Document Type: Article

References (26)

1. A Acheson JC Conover JP Fandl TM DeChiara M Russell A Thadani SP Squinto GD Yancopoulos RM Lindsay 1995 A BDNF autocrine loop in adult sensory neurons prevents cell death Nature 374 450 453 7700353 10.1038/374450a0 1:CAS:528:DyaK2MXkslSlsbw%3D
2. N Ady JM Zucker B Asselain V Edeline F Bonnin J Michon R Gongora L Manil 1995 A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma Eur J Cancer 31A 256 261 7718334 10.1016/0959-8049(94)00509-4 1:STN:280:DyaK2M3jsVCiuw%3D%3D
3. S Asgharzadeh R Pique-Regi R Sposto H Wang Y Yang H Shimada K Matthay J Buckley A Ortega RC Seeger 2006 Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification J Natl Cancer Inst 98 1193 1203 16954472 10.1093/jnci/djj330 1:CAS:528: DC%2BD28Xps1yjtL0%3D (Pubitemid 44390990)
4. GM Brodeur JM Maris DJ Yamashiro MD Hogarty PS White 1997 Biology and genetics of human neuroblastomas J Pediatr Hematol Oncol 19 93 101 9149737 10.1097/00043426-199703000-00001 1:STN:280:DyaK2s3ptlynsQ%3D%3D (Pubitemid 27200550)
5. GM Brodeur JE Minturn R Ho AM Simpson R Iyer CR Varela JE Light V Kolla AE Evans 2009 Trk receptor expression and inhibition in neuroblastomas Clin Cancer Res 15 3244 3250 19417027 10.1158/1078-0432.CCR-08-1815 1:CAS:528:DC%2BD1MXmtVKmtbk%3D
6. GM Brodeur J Pritchard F Berthold NL Carlsen V Castel RP Castelberry B De Bernardi AE Evans M Favrot F Hedborg, et al. 1993 Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment J Clin Oncol 11 1466 1477 8336186 1:STN:280:DyaK3szivFCrug%3D%3D (Pubitemid 23228250)
7. AE Evans KD Kisselbach X Liu A Eggert N Ikegaki AM Camoratto C Dionne GM Brodeur 2001 Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB Med Pediatr Oncol 36 181 184 11464878 10.1002/1096-911X(20010101)36: 1<181::AID-MPO1043>3.0.CO;2-Q 1:STN:280:DC%2BD3MvhsV2jsg%3D%3D (Pubitemid 32053026)
8. AE Evans KD Kisselbach DJ Yamashiro N Ikegaki AM Camoratto CA Dionne GM Brodeur 1999 Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts Clin Cancer Res 5 3594 3602 10589776 1:CAS:528:DyaK1MXotV2gtro%3D
9. RE George S Li C Medeiros-Nancarrow D Neuberg K Marcus RC Shamberger M Pulsipher SA Grupp L Diller 2006 High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update J Clin Oncol 24 2891 2896 16782928 10.1200/JCO.2006.05.6986 (Pubitemid 46630591)
10. R Iyer AE Evans X Qi R Ho JE Minturn H Zhao N Balamuth JM Maris GM Brodeur 2010 Lestaurtinib enhances the anti-tumor efficacy of chemotherapy in murine xenograft models of neuroblastoma Clin Cancer Res 16 1478 1485 20179224 10.1158/1078-0432.CCR-09-1531 1:CAS:528:DC%2BC3cXisFSis7o%3D
11. S Knapper AK Burnett T Littlewood WJ Kell S Agrawal R Chopra R Clark MJ Levis D Small 2006 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy Blood 108 3262 3270 16857985 10.1182/blood-2006-04-015560 1:CAS:528:DC%2BD28Xht1ahs7fJ
12. M Levis P Brown BD Smith A Stine R Pham R Stone D Deangelo I Galinsky F Giles E Estey H Kantarjian P Cohen Y Wang J Roesel JE Karp D Small 2006 Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors Blood 108 3477 3483 16857987 10.1182/blood-2006-04-015743 1:CAS:528:DC%2BD28Xht1egu77N
13. JM Maris MD Hogarty R Bagatell SL Cohn 2007 Neuroblastoma Lancet 369 2106 2120 17586306 10.1016/S0140-6736(07)60983-0 1:CAS:528:DC%2BD2sXmvVKqtb0%3D (Pubitemid 46935947)
14. JL Marshall H Kindler J Deeken P Bhargava NJ Vogelzang N Rizvi T Luhtala S Boylan M Dordal P Robertson MJ Hawkins MJ Ratain 2005 Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor Invest New Drugs 23 31 37 15528978 10.1023/B:DRUG.0000047103.64335.b0 1:CAS:528:DC%2BD2cXptlSlu7Y%3D (Pubitemid 39505949)
15. K Matsumoto RK Wada JM Yamashiro DR Kaplan CJ Thiele 1995 Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells Cancer Res 55 1798 1806 7712490 1:CAS:528:DyaK2MXltVSlsb0%3D
16. KK Matthay JG Villablanca RC Seeger DO Stram RE Harris NK Ramsay P Swift H Shimada CT Black GM Brodeur RB Gerbing CP Reynolds 1999 Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group N Engl J Med 341 1165 1173 10519894 10.1056/NEJM199910143411601 1:STN:280: DyaK1MvjsFGnsg%3D%3D (Pubitemid 29480654)
17. SJ Miknyoczki CA Dionne AJ Klein-Szanto BA Ruggeri 1999 The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness Ann N Y Acad Sci 880 252 262 10415871 10.1111/j.1749-6632.1999. tb09530.x 1:CAS:528:DyaK1MXkslGls7Y%3D (Pubitemid 29349134)
18. A Nakagawara 2001 Trk receptor tyrosine kinases: a bridge between cancer and neural development Cancer Lett 169 107 114 11431098 10.1016/S0304-3835(01) 00530-4 1:CAS:528:DC%2BD3MXks1Onu7Y%3D (Pubitemid 32595557)
19. A Nakagawara M Arima-Nakagawara NJ Scavarda CG Azar AB Cantor GM Brodeur 1993 Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma N Engl J Med 328 847 854 8441429 10.1056/NEJM199303253281205 1:STN:280:DyaK3s7otVyltA%3D%3D (Pubitemid 23084339)
20. A Nakagawara CG Azar NJ Scavarda GM Brodeur 1994 Expression and function of TRK-B and BDNF in human neuroblastomas Mol Cell Biol 14 759 767 8264643 1:CAS:528:DyaK2cXhtVemtLY%3D
21. FP Santos HM Kantarjian N Jain T Manshouri DA Thomas G Garcia-Manero D Kennedy Z Estrov J Cortes S Verstovsek 2009 Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis Blood 115 1131 1136 20008298 10.1182/blood-2009-10-246363
22. BD Smith M Levis M Beran F Giles H Kantarjian K Berg KM Murphy T Dauses J Allebach D Small 2004 Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 103 3669 3676 14726387 10.1182/blood-2003-11-3775 1:CAS:528:DC%2BD2cXjvF2itb4%3D (Pubitemid 38596280)
23. A Tacconelli AR Farina L Cappabianca G Desantis A Tessitore A Vetuschi R Sferra N Rucci B Argenti I Screpanti A Gulino AR Mackay 2004 TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma Cancer Cell 6 347 360 15488758 10.1016/j.ccr.2004.09.011 1:CAS:528:DC%2BD2cXpsF2rt7c%3D (Pubitemid 39361436)
24. A Tacconelli AR Farina L Cappabianca A Gulino AR Mackay 2005 TrkAIII. A novel hypoxia-regulated alternative TrkA splice variant of potential physiological and pathological importance Cell Cycle 4 8 9 15611661 10.4161/cc.4.1.1349 1:CAS:528:DC%2BD28XjtVert74%3D (Pubitemid 41038914)
25. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
26. CJ Thiele Z Li AE McKee 2009 On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology Clin Cancer Res 15 5962 5967 19755385 10.1158/1078-0432.CCR-08-0651 1:CAS:528:DC%2BD1MXhtF2ltbnI